Efficacy and Safety of Nasal Glucagon for Treatment of Hypoglycemia in Adults
Status:
Completed
Trial end date:
2015-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the efficacy, pharmacokinetics (PK), pharmacodynamics
(PD), and safety of 3 milligrams (mg) glucagon (glucagon nasal powder) administered nasally
compared with commercially available glucagon given by intramuscular injection.
Phase:
Phase 3
Details
Lead Sponsor:
Eli Lilly and Company Jaeb Center for Health Research
Collaborators:
Eli Lilly and Company Locemia Solutions ULC T1D Exchange Clinic Network Coordinating Center